KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares IssuedShares OutstandingShares OutstandingShares Repurchased
Ratios

Fulgent Genetics (FLGT) Shares Outstanding (2016 - 2026)

Fulgent Genetics' Shares Outstanding history spans 12 years, with the latest figure at $34.9 million for Q1 2026.

  • On a quarterly basis, Shares Outstanding rose 13.88% to $34.9 million in Q1 2026 year-over-year; TTM through Mar 2026 was $34.9 million, a 13.88% increase, with the full-year FY2025 number at $31.1 million, up 0.78% from a year prior.
  • Shares Outstanding hit $28.9 million in Q1 2026 for Fulgent Genetics, down from $31.1 million in the prior quarter.
  • Over the last five years, Shares Outstanding for FLGT hit a ceiling of $31.1 million in Q4 2025 and a floor of $28.9 million in Q1 2026.
  • Historically, Shares Outstanding has averaged $30.2 million across 5 years, with a median of $30.3 million in 2024.
  • Biggest five-year swings in Shares Outstanding: dropped 2.39% in 2022 and later grew 13.88% in 2026.
  • Tracing FLGT's Shares Outstanding over 5 years: stood at $29.4 million in 2022, then grew by 0.73% to $29.7 million in 2023, then increased by 4.01% to $30.8 million in 2024, then rose by 0.78% to $31.1 million in 2025, then rose by 12.19% to $34.9 million in 2026.
  • Business Quant data shows Shares Outstanding for FLGT at $34.9 million in Q1 2026, $31.1 million in Q4 2025, and $30.9 million in Q3 2025.